Notícias Corporativas

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, will exclusively distribute Spectrila® via a Managed Access Program for targeted Healthcare Providers in

Merck’s Keytruda (Pembrolizumab) showed better results than chemotherapy at improving overall survival among first-line patients with non-small cell lung cancer in a trial whose results

AstraZeneca’s Tagrisso has been approved by FDA as a first-line treatment for patients with metastatic non-small-cell lung cancer characterized by epidermal growth factor receptor (EGFR)

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by Amomed Pharma to exclusively distribute Empressin® via a Managed Access

Read the full interview, appeared on the magazine Healthcare and Life Sciences Review with our CEO, Mr. Yaron Spigel, regarding the uniqueness of FarmaMondo business

FarmaMondo SA announces it has established operations through its Global Access business unit into several south EU markets to allow direct to hospital supply of

FarmaMondo SA announces it has established operations in Mexico to allow direct to hospital supply of unlicensed medicines, to cover spontaneous needs and our portfolio

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by EUSA Pharma to exclusively distribute Qarziba® via a Managed Access